

## Special Issue

# Bioengineering Strategies for Developing Vaccines

### Message from the Guest Editors

For this Special Issue, we are calling for research papers and reviews related to the bioengineering of vaccines, including, but not limited to, antigen engineering, vaccine platform development, vaccine delivery systems, and the application of artificial intelligence to vaccine design. We hope this Special Issue provides an opportunity to learn about updated bioengineering advances in vaccine development, both innovative methods and real-world applications, for advancing vaccine efficacy and safety.

---

### Guest Editors

Prof. Dr. Chen Zhao

Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China

Dr. Jiayi Shu

Center of Biotherapy, Zhongshan Hospital, Fudan University, Shanghai 200032, China

---

### Deadline for manuscript submissions

30 June 2026



# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



[mdpi.com/journal/vaccines](https://www.mdpi.com/journal/vaccines)

*Vaccines*

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

vaccines@mdpi.com

[mdpi.com/journal/vaccines](https://www.mdpi.com/journal/vaccines)

[vaccines](https://www.mdpi.com/journal/vaccines)





# Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](http://mdpi.com/journal/vaccines)

## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

